- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01053494
Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer
The TOUCH Project: Reducing Distress and Promoting Quality of Life Via Caregiver Massage of Children Undergoing Treatment for Cancer
Study Overview
Status
Conditions
- Unspecified Childhood Solid Tumor, Protocol Specific
- Primary Myelofibrosis
- Polycythemia Vera
- Essential Thrombocythemia
- Stage I Multiple Myeloma
- Stage II Multiple Myeloma
- Stage III Multiple Myeloma
- Chronic Myelomonocytic Leukemia
- Juvenile Myelomonocytic Leukemia
- Burkitt Lymphoma
- Secondary Acute Myeloid Leukemia
- Childhood Acute Myeloid Leukemia in Remission
- Angioimmunoblastic T-cell Lymphoma
- Accelerated Phase Chronic Myelogenous Leukemia
- Childhood Acute Lymphoblastic Leukemia in Remission
- Childhood Chronic Myelogenous Leukemia
- Childhood Myelodysplastic Syndromes
- Chronic Phase Chronic Myelogenous Leukemia
- Cutaneous B-cell Non-Hodgkin Lymphoma
- Intraocular Lymphoma
- Post-transplant Lymphoproliferative Disorder
- Recurrent Childhood Acute Lymphoblastic Leukemia
- Recurrent Childhood Acute Myeloid Leukemia
- Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma
- Recurrent Mycosis Fungoides/Sezary Syndrome
- Refractory Multiple Myeloma
- Relapsing Chronic Myelogenous Leukemia
- Prolymphocytic Leukemia
- Refractory Chronic Lymphocytic Leukemia
- Stage III Cutaneous T-cell Non-Hodgkin Lymphoma
- Stage III Mycosis Fungoides/Sezary Syndrome
- Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma
- Stage IV Mycosis Fungoides/Sezary Syndrome
- Chronic Neutrophilic Leukemia
- Refractory Hairy Cell Leukemia
- T-cell Large Granular Lymphocyte Leukemia
- Acute Undifferentiated Leukemia
- Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
- Mast Cell Leukemia
- Stage 0 Chronic Lymphocytic Leukemia
- Stage I Chronic Lymphocytic Leukemia
- Stage II Chronic Lymphocytic Leukemia
- Primary Systemic Amyloidosis
- Childhood Diffuse Large Cell Lymphoma
- Childhood Grade III Lymphomatoid Granulomatosis
- Childhood Immunoblastic Large Cell Lymphoma
- Childhood Nasal Type Extranodal NK/T-cell Lymphoma
- Recurrent Childhood Anaplastic Large Cell Lymphoma
- Recurrent Childhood Grade III Lymphomatoid Granulomatosis
- Recurrent Childhood Large Cell Lymphoma
- Recurrent Childhood Lymphoblastic Lymphoma
- Recurrent Childhood Small Noncleaved Cell Lymphoma
- Recurrent/Refractory Childhood Hodgkin Lymphoma
- Contiguous Stage II Mantle Cell Lymphoma
- Noncontiguous Stage II Mantle Cell Lymphoma
- Progressive Hairy Cell Leukemia, Initial Treatment
- Stage III Chronic Lymphocytic Leukemia
- Stage IV Chronic Lymphocytic Leukemia
- Stage III Childhood Hodgkin Lymphoma
- Stage IV Childhood Hodgkin Lymphoma
- Blastic Phase Chronic Myelogenous Leukemia
- Meningeal Chronic Myelogenous Leukemia
- Chronic Eosinophilic Leukemia
- Extramedullary Plasmacytoma
- Isolated Plasmacytoma of Bone
- Stage I Childhood Anaplastic Large Cell Lymphoma
- Stage I Childhood Hodgkin Lymphoma
- Stage I Childhood Large Cell Lymphoma
- Stage I Childhood Lymphoblastic Lymphoma
- Stage I Childhood Small Noncleaved Cell Lymphoma
- Stage I Cutaneous T-cell Non-Hodgkin Lymphoma
- Stage II Childhood Anaplastic Large Cell Lymphoma
- Stage II Childhood Hodgkin Lymphoma
- Stage II Childhood Large Cell Lymphoma
- Stage II Childhood Lymphoblastic Lymphoma
- Stage II Childhood Small Noncleaved Cell Lymphoma
- Stage II Cutaneous T-cell Non-Hodgkin Lymphoma
- Stage III Childhood Anaplastic Large Cell Lymphoma
- Stage III Childhood Large Cell Lymphoma
- Stage III Childhood Lymphoblastic Lymphoma
- Stage III Childhood Small Noncleaved Cell Lymphoma
- Stage IV Childhood Anaplastic Large Cell Lymphoma
- Stage IV Childhood Large Cell Lymphoma
- Stage IV Childhood Lymphoblastic Lymphoma
- Stage IV Childhood Small Noncleaved Cell Lymphoma
- Stage I Mycosis Fungoides/Sezary Syndrome
- Stage II Mycosis Fungoides/Sezary Syndrome
Detailed Description
PRIMARY OBJECTIVES:
I. To determine the feasibility and acceptability of conducting a massage intervention with childhood cancer patients and their primary caregivers.
II. To investigate feasibility of implementing a brief targeted massage training protocol with caregivers.
III. To identify barriers to recruitment, intervention adherence, and full study completion by consented families.
IV. To assess preliminary effectiveness of the massage intervention in reducing caregiver and child psychological distress (anxiety, depression, parenting stress) and promoting child health-related quality of life.
V. To compare outcome data between two intervention arms (TOUCH: child massage only; TOUCH+: Caregiver massage plus child massage) and between each arm and a wait list control condition.
VI. To utilize the pilot data in a development of contextually specific and targeted grant application for a fully powered randomized controlled trial of the efficacy of caregiver massage of children undergoing treatment for cancer.
SECONDARY OBJECTIVES:
I. To investigate reciprocal change in self-reported psychosocial functioning within the caregiver-child dyad from baseline to post-intervention.
II. To assess impact of massage intervention upon levels of a stress biomarker (cortisol) in caregivers and children and to assess associations of cortisol levels with self-reported psychosocial functioning.
OUTLINE: Patients and their caregivers are randomized to 1 of 3 treatment arms.
ARM I (WAITLIST CONTROL GROUP): Patients and caregivers receive standard of care and are offered the massage intervention after 8 weeks.
ARM II (TOUCH): Caregivers undergo a 60-minute training session on simple massage techniques, including the "Massage Toolkit," comprising Swedish Massage and Trigger Point Therapy Massage, at week 0 and a booster 60-minute massage training session at week 4 with a licensed massage therapist. Caregivers are instructed to massage their children for at least 3 20-minute sessions per week for 8 weeks.
ARM III (TOUCH+): Caregivers undergo a 60-minute training session on simple massage techniques, including the "Massage Toolkit," comprising Swedish Massage and Trigger Point Therapy Massage, at week 0 and a booster 60-minute massage training session at week 4 with a licensed massage therapist. Caregivers are instructed to massage their children for at least 3 20-minute sessions per week for 8 weeks. Caregivers also receive a 45-minute massage by the massage therapist.
Patients complete questionnaires at weeks 0, 8, and 16.
After completion of study treatment, patients and caregivers are followed for 8 weeks.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
North Carolina
-
Winston-Salem, North Carolina, United States, 27157
- Wake Forest University Health Sciences
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Signed protocol specific informed consent by the child's caregiver Assent by the child Caregiver is at least 18 years of age The child is currently treated for cancer (chemotherapy alone, radiation therapy alone, chemotherapy and radiation therapy, chemotherapy and surgery, or radiation therapy and surgery) at Wake Forest Baptist Health (WFBH) Pediatric Oncology The child has at least 16 weeks remaining on their treatment regimen The caregiver and child understand written and spoken English The child has no medical or functional contraindications reported by his/her attending\physician
Exclusion Criteria:
Parents/caregivers who have previously provided consistent massage for their child will be excluded from the study Child is receiving radiation only
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Arm I (WAITLIST CONTROL GROUP)
Patients and caregivers receive standard of care and are offered the massage intervention after 8 weeks.
|
Ancillary studies
Ancillary studies
Other Names:
Undergo standard follow-up care
|
|
Experimental: Arm II (TOUCH)
Caregivers undergo a 60-minute training session on simple massage techniques, including the "Massage Toolkit," comprising Swedish Massage and Trigger Point Therapy Massage, at week 0 and a booster 60-minute massage training session at week 4 with a licensed massage therapist.
Caregivers are instructed to massage their children for at least 3 20-minute sessions per week for 8 weeks.
|
Ancillary studies
Ancillary studies
Other Names:
Undergo massage therapy
Other Names:
Undergo massage by caregiver
|
|
Experimental: Arm III (TOUCH+)
Caregivers undergo a 60-minute training session on simple massage techniques, including the "Massage Toolkit," comprising Swedish Massage and Trigger Point Therapy Massage, at week 0 and a booster 60-minute massage training session at week 4 with a licensed massage therapist.
Caregivers are instructed to massage their children for at least 3 20-minute sessions per week for 8 weeks.
Caregivers also receive a 45-minute massage by the massage therapist.
|
Ancillary studies
Ancillary studies
Other Names:
Undergo massage therapy
Other Names:
Undergo massage by caregiver
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Feasibility and acceptability of conducting a massage intervention with childhood cancer patients and their primary caregivers
Time Frame: Up to 16 weeks
|
Up to 16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Effectiveness of caregiver massage to reduce child and caregiver distress and promote child health-related quality of life
Time Frame: Baseline
|
Baseline
|
|
Effectiveness of caregiver massage to reduce child and caregiver distress and promote child health-related quality of life
Time Frame: Week 8
|
Week 8
|
|
Effectiveness of caregiver massage to reduce child and caregiver distress and promote child health-related quality of life
Time Frame: Week 16
|
Week 16
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Janet Tooze, PhD, Wake Forest University Health Sciences
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Metabolic Diseases
- Virus Diseases
- Infections
- Immune System Diseases
- Neoplasms, Connective and Soft Tissue
- Neoplasms by Histologic Type
- Neoplasms
- Lymphatic Diseases
- Immunoproliferative Disorders
- Neoplasms by Site
- Disease Attributes
- Disease
- Bone Marrow Diseases
- Hematologic Diseases
- Hemorrhagic Disorders
- Myeloproliferative Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- DNA Virus Infections
- Bacterial Infections and Mycoses
- Neoplastic Processes
- Proteostasis Deficiencies
- Tumor Virus Infections
- Blood Coagulation Disorders
- Blood Platelet Disorders
- Precancerous Conditions
- Myelodysplastic-Myeloproliferative Diseases
- Leukocyte Disorders
- Epstein-Barr Virus Infections
- Herpesviridae Infections
- Leukemia, B-Cell
- Neoplasms, Connective Tissue
- Eosinophilia
- Cell Transformation, Neoplastic
- Carcinogenesis
- Eye Neoplasms
- Lymphadenopathy
- Bone Marrow Neoplasms
- Hematologic Neoplasms
- Leukemia, T-Cell
- Mastocytosis, Systemic
- Mastocytosis
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
- Syndrome
- Myelodysplastic Syndromes
- Primary Myelofibrosis
- Multiple Myeloma
- Neoplasms, Plasma Cell
- Leukemia
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Hodgkin Disease
- Recurrence
- Lymphoma, Non-Hodgkin
- Immunoglobulin Light-chain Amyloidosis
- Amyloidosis
- Leukemia, Myelomonocytic, Acute
- Leukemia, Myelomonocytic, Chronic
- Leukemia, Myelomonocytic, Juvenile
- Mycoses
- Thrombocytosis
- Thrombocythemia, Essential
- Burkitt Lymphoma
- Lymphoma, Mantle-Cell
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Lymphoma, Large-Cell, Immunoblastic
- Plasmablastic Lymphoma
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Hypereosinophilic Syndrome
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Peripheral
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Leukemia, Myeloid, Chronic-Phase
- Blast Crisis
- Lymphoma, T-Cell, Cutaneous
- Plasmacytoma
- Mycosis Fungoides
- Sezary Syndrome
- Lymphoma, Large-Cell, Anaplastic
- Lymphomatoid Granulomatosis
- Leukemia, Myeloid, Accelerated Phase
- Lymphoma, Extranodal NK-T-Cell
- Intraocular Lymphoma
- Lymphoproliferative Disorders
- Immunoblastic Lymphadenopathy
- Leukemia, Prolymphocytic
- Polycythemia Vera
- Polycythemia
- Leukemia, Hairy Cell
- Leukemia, Large Granular Lymphocytic
- Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
- Leukemia, Mast-Cell
- Leukemia, Neutrophilic, Chronic
Other Study ID Numbers
- IRB00011619
- NCI-2009-01456 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- CCCWFU 97709 (Other Identifier: Wake Forest University Health Sciences)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Unspecified Childhood Solid Tumor, Protocol Specific
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingCollection and Storage of Tissue Samples From Patients Undergoing Surgery For Suspected Solid TumorsUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Kantonsspital GraubuendenUnknownUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificSwitzerland
-
National Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Vanderbilt UniversityNational Cancer Institute (NCI)TerminatedUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
University of ChicagoNational Cancer Institute (NCI)CompletedSirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By SurgeryUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)WithdrawnUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol Specific
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyWithdrawnUnspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol Specific | Hematopoietic/Lymphoid CancerUnited States
-
Children's Cancer and Leukaemia GroupUnknownUnspecified Childhood Solid Tumor, Protocol SpecificIreland, United Kingdom
Clinical Trials on questionnaire administration
-
Fondazione Don Carlo Gnocchi OnlusCompleted
-
Centre Oscar LambretCentre Hospitalier Universitaire de BesanconTerminated
-
Hospital Clínico Universitario de ValladolidRed Centinela Sanitaria de Castilla y León (RCSCYL); Centro Nacional de Gripe... and other collaboratorsRecruitingMigraine | Headache Disorders | Viral Infection | Influenza -Like Illness | Head PainSpain
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingBreast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | COVID-19 Infection | Hereditary Breast CarcinomaUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingAdvanced Malignant Solid Neoplasm | Hematopoietic and Lymphoid System NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Recurrent Plasma Cell Myeloma | Caregiver | Recurrent LeukemiaUnited States
-
Gulseren Demir KarakilicCompletedMusculoskeletal Diseases | Chronic PainTurkey (Türkiye)
-
I.M. Sechenov First Moscow State Medical UniversityAgency of Social Information St. PetersburgActive, not recruiting
-
I.M. Sechenov First Moscow State Medical UniversityActive, not recruitingShoulder ArthropathyRussian Federation
-
Karolinska University HospitalSahlgrenska University Hospital, Sweden; University Hospital, Linkoeping; Skane...Active, not recruitingQuality of Life | Vulvar CancerSweden